Prescription drug fraud defense

The federal-state framework for prescription drug fraud

Prescription drug fraud is prosecuted under overlapping federal and Texas statutes — 21 U.S.C. § 841 for unauthorized prescribing, § 843(a)(3) for acquisition by deception, § 846 for conspiracy, and Tex. H&SC § 481.129 at the state level. The choice of charging forum drives every other strategic decision.

21 U.S.C. § 841(a) — knowing and intentional distribution

The principal federal statute prohibits knowingly or intentionally manufacturing, distributing, or dispensing a controlled substance "except as authorized." For a registered practitioner — physician, dentist, veterinarian, advanced practice nurse, or physician assistant with DEA registration — the "except as authorized" qualifier ties to 21 C.F.R. § 1306.04(a): legitimate medical purpose, in the usual course of professional practice. Penalties vary by schedule and quantity but reach 20 years for ordinary Schedule II distribution; 20 years to life for quantity-threshold cases; and a maximum of life imprisonment when death or serious bodily injury results from use of the substance distributed by the defendant under § 841(b)(1)(C).

21 U.S.C. § 843(a)(3) — acquisition by deception

A separate federal statute prohibits knowingly or intentionally acquiring or obtaining possession of a controlled substance "by misrepresentation, fraud, forgery, deception, or subterfuge." This is the principal federal statute for doctor-shopping prosecutions and for patient prosecutions involving forged or altered prescriptions. The maximum sentence under § 843(d)(1) is 4 years (12 years for repeat offenders) plus fine — substantially less than § 841 — but the elements are easier for the government to prove because no quantity threshold applies and no medical-practice analysis is required. Section 843(a)(3) is also frequently used as a lever in patient cooperation arrangements against prescribers.

21 U.S.C. § 846 — conspiracy

The federal conspiracy statute covering all CSA offenses. Penalties are the same as the substantive offense — there is no overt-act requirement under Salinas v. United States, 522 U.S. 52 (1997). Section 846 produces the umbrella charge in most multi-defendant pill-mill indictments, joining prescribers, clinic staff, pharmacy operators, marketers, and patient recruiters into a single conspiracy theory. Conspiracy liability extends to reasonably foreseeable acts of co-conspirators under Pinkerton v. United States, 328 U.S. 640 (1946) — making a clinic owner potentially liable for prescribing decisions made by independent contractor physicians at the clinic, depending on the scope-of-agreement analysis.

Texas H&SC § 481.129 — state prescription fraud

Texas's state-law analog covers the same essential conduct — acquisition or distribution of a controlled substance by misrepresentation, fraud, forgery, deception, or subterfuge. The default grade is a state jail felony (180 days to 2 years, fine up to $10,000); the offense escalates to a 3rd-degree felony (2-10 years, fine up to $10,000) if the controlled substance is listed in Penalty Group 1 or 2 — which captures most clinically prescribed opioids (hydrocodone, oxycodone, fentanyl, methadone, morphine), methamphetamine, cocaine, and MDMA. Texas may prosecute § 481.129 in parallel with or in lieu of federal charges, with charging decisions typically driven by penalty exposure, federal-state coordination, and venue considerations.

Prescription drug fraud lives at the intersection of three distinct enforcement architectures. The federal Controlled Substances Act framework — § 841, § 843(a)(3), § 846 — is enforced by the DEA Diversion Control Division working in tight coordination with the U.S. Attorney's Offices and the DOJ Healthcare Fraud Strike Force in cases of substantial scale. The Texas state framework under Health & Safety Code Chapter 481 is enforced by Department of Public Safety narcotics investigators, county and district attorneys, and the Texas Medical Board / Texas State Board of Pharmacy on the administrative side. The Texas Medical Board administrative architecture under Occupations Code Chapters 151-165 operates in parallel to either criminal track and produces license suspensions, revocations, and restrictions independently of the criminal disposition. The defense team must coordinate across all three architectures from the first weeks of representation, because admissions and evidence in any one can migrate to the others.

Charging-forum selection is the first major strategic question. Federal authorities tend to charge cases involving (1) substantial volume or organized operations; (2) interstate elements; (3) overlapping healthcare fraud or money-laundering exposure; (4) coordination with parallel qui tam False Claims Act litigation; or (5) DOJ Strike Force priority categories. Texas authorities tend to charge cases involving (1) single-defendant patient prosecutions; (2) lower-volume or single-incident allegations; (3) cases originating from local DPS or police investigations rather than DEA-led operations; or (4) cases where federal prosecutors have declined for resource reasons. The penalty exposure is usually higher federally, but the federal Sentencing Guidelines under § 2D1.1 and § 2D1.11 can produce calculation-driven sentences below the statutory maximums in many first-offender cases — while a Texas 3rd-degree felony (2-10) for a PG1 § 481.129 violation produces shorter floor exposure than a § 841 conviction with applicable Guidelines enhancements.

21 U.S.C. § 841 and the Ruan knowledge standard

Section 841 is the principal federal prescription-fraud statute for prescribers. After Ruan v. United States, 597 U.S. 450 (2022), the government must prove the defendant subjectively knew that the prescribing conduct fell outside the usual course of professional practice — a substantial change that reshaped pill-mill defense.

The Supreme Court's 2022 decision in Ruan v. United States, 597 U.S. 450, restructured the defense landscape for federal prescription drug fraud prosecutions targeting prescribers. The Court unanimously held that the mens rea analysis under 21 U.S.C. § 841(a) extends to the statutory phrase "except as authorized" — meaning that once a defendant produces evidence that his prescriptions were authorized (issued for legitimate medical purpose, in the usual course of professional practice), the government must prove beyond a reasonable doubt that the defendant subjectively knew or intended that the conduct was unauthorized. The decision applied the Court's long-standing scienter-extends-to-statutory-elements framework from United States v. X-Citement Video, 513 U.S. 64 (1994), and Liparota v. United States, 471 U.S. 419 (1985), to the controlled-substance context for the first time.

Pre-Ruan, several circuits had applied an "objective good-faith" or "reasonable physician" standard — once the government proved the prescription was not for a legitimate medical purpose by objective standards (typically established through expert testimony), the defendant could be convicted regardless of his subjective belief about authorization. Ruan rejected that approach. The Court emphasized that the "except as authorized" clause is a statutory element distinguishing authorized practice (lawful) from unauthorized distribution (felony), and the historical presumption of scienter in criminal statutes requires that the government prove mens rea as to that distinguishing element. The Court's reasoning aligned § 841 prosecutions of prescribers with the broader scienter doctrine while leaving room for circumstantial evidence of subjective knowledge — atypical practice patterns, ignorance of patient histories, missed standard-of-care signals, and patterns that "no reasonable physician" would believe lawful can all support a jury inference of subjective knowledge.

The post-Ruan defense landscape in pill-mill prosecutions has been substantially reshaped. Defense expert testimony on standard medical practice — historically used to challenge the government's evidence that the prescriptions deviated from professional norms — now plays a more important role as evidence of the defendant's subjective good-faith belief that he was practicing within the standard of care. Documentation of clinical reasoning, treatment plans, follow-up protocols, monitoring of patient outcomes, urine drug screens, pain-contract compliance, and consultations with colleagues becomes critical evidence of the subjective good-faith state. United States v. Hammond, 996 F.3d 374 (6th Cir. 2021), the Sixth Circuit's post-Ruan sufficiency-review decision, illustrates how the subjective-knowledge framework operates in appellate practice — the court examined the totality of evidence supporting the inference that the physician knew his prescribing was unauthorized, including patient testimony, surveillance evidence, financial patterns, and atypical clinical practices.

Practical charging effects have been significant. DOJ Healthcare Fraud Strike Force units have continued to bring pill-mill prosecutions post-Ruan, but the threshold for credible charging has risen — the government must now develop subjective-knowledge evidence (informant testimony from clinic staff, surveillance of office practices, financial records showing patterns consistent with intentional drug-diversion rather than ordinary medical practice, recorded conversations) rather than relying on expert testimony about objective unreasonableness. Defense plea-negotiation leverage has correspondingly increased. The most consequential post-Ruan litigation in the Northern and Eastern Districts of Texas has involved how juries are instructed on the subjective-knowledge element and what circumstantial evidence the government can use to prove it. Practitioners charged with controlled-substance offenses arising out of medical practice should ensure their defense counsel is current on Ruan and its progeny — the framework has been one of the most significant pro-defense developments in federal criminal law in the last decade.

Acquisition by deception under 21 U.S.C. § 843(a)(3)

Section 843(a)(3) is the principal federal statute for patient-side prescription fraud — doctor-shopping, forged prescriptions, altered prescriptions, and misrepresentation to prescribers. The maximum sentence is 4 years (12 years for repeat offenders) plus fine.

Section 843(a)(3) of Title 21 prohibits any person from knowingly or intentionally acquiring or obtaining possession of a controlled substance "by misrepresentation, fraud, forgery, deception, or subterfuge." The statute is the principal federal mechanism for charging patient-side prescription drug fraud — including doctor-shopping, forgery or alteration of prescription forms, theft and use of physician DEA numbers, deception of pharmacists about prior prescriptions or duplicate-fill status, false statements during clinical encounters to obtain prescriptions, and use of fictitious or stolen identities to obtain medications. The mens rea standard is "knowingly or intentionally" — and unlike § 841 prosecutions of prescribers, the Ruan subjective-knowledge framework operates straightforwardly here because the conduct itself (forgery, deception) involves no medical-practice ambiguity.

The penalty structure under § 843(d)(1) caps at 4 years for first offenders and 12 years for second or subsequent felony drug offenders. Fines are imposed under 18 U.S.C. § 3571 (up to $250,000 for individuals, $500,000 for organizations, or twice the gain or loss). Section 843(a)(3) is also frequently used as a charging lever in patient cooperation arrangements — patients with substantial information about a pill-mill operation or pharmacist diversion scheme are often offered favorable § 843(a)(3) plea dispositions in exchange for testimony against more culpable principals. The statute can also be used as a 5K1.1 substantial-assistance vehicle in larger investigations, with cooperating patients providing both documentary evidence (prescriptions, payment records, text messages) and testimony.

Federal U.S. Sentencing Guidelines § 2D2.2 applies to § 843(a)(3) violations, with base offense levels of 4 to 8 depending on the substance and quantity involved. Guidelines ranges for first-offender § 843(a)(3) cases typically fall in the 0-6 month range with no enhancements — making this category an area where well-positioned defendants frequently obtain probation-only or short-custody dispositions. The contrast with § 841 prescribing cases is stark — § 841 produces multi-year Guidelines ranges driven by drug-quantity tables under § 2D1.1, while § 843(a)(3) produces probation-zone Guidelines outcomes in the substantial majority of patient prosecutions.

State-court parallels under Tex. H&SC § 481.129 cover the same essential conduct and produce comparable patient-side outcomes. Federal prosecutors typically reserve § 843(a)(3) charges for cases that arise as part of broader pill-mill investigations or that involve interstate or organized-crime elements; smaller patient cases typically remain in state court under § 481.129. The defense strategy in § 843(a)(3) cases focuses on (1) negating the "knowing or intentional" mens rea where the defendant relied on a prescription written by an authorized prescriber without knowledge that the prescriber was operating outside the usual course of professional practice; (2) challenging documentary evidence of forgery or alteration through forensic-document examination; (3) Fourth Amendment challenges to pharmacy and clinic records obtained without proper subpoenas or warrants; and (4) substance-use-disorder mitigation arguments at sentencing.

Texas prescription fraud under § 481.129

Tex. Health & Safety Code § 481.129 is the principal Texas state statute covering prescription fraud, doctor-shopping, and forgery of controlled-substance prescriptions. State jail felony default; 3rd-degree felony (2-10 years) for Penalty Group 1 or 2 substances.

Texas Health & Safety Code § 481.129 is the principal state-law statute covering prescription drug fraud. The statute makes it a felony to knowingly possess, obtain, attempt to possess or obtain, distribute, attempt to distribute, deliver, or attempt to deliver a controlled substance, controlled-substance analogue, or dangerous drug by misrepresentation, fraud, forgery, deception, or subterfuge. The statute also covers issuance of false or counterfeit prescriptions, possession of prescription forms with intent to use them unlawfully, and false statements made to obtain controlled-substance prescriptions. The mens rea is "knowingly" — the defendant must be aware of the unlawful nature of the acquisition, distribution, or representation.

The penalty structure under § 481.129 is graded by the substance involved. The default grade is a state jail felony — 180 days to 2 years in a state jail facility, plus a fine up to $10,000 — for offenses involving controlled substances in Penalty Group 3, 4, or in the dangerous-drug category. The offense escalates to a 3rd-degree felony (2-10 years in TDCJ plus fine up to $10,000) when the controlled substance is listed in Penalty Group 1 or 2 — which captures most clinically prescribed opioids (hydrocodone, oxycodone, fentanyl, methadone, morphine, hydromorphone), most amphetamines and stimulants used in prescription form, methamphetamine, cocaine, MDMA, and most other commonly abused Schedule II controlled substances. The result is that a single misrepresentation in obtaining a hydrocodone prescription is potentially a 3rd-degree felony exposure under Texas law.

Texas additionally regulates the prescribing process under Occupations Code §§ 481.073-481.081, the Texas Controlled Substances Act practitioner regulations. These provisions require that prescriptions be issued in good faith for a legitimate medical purpose; that prescribers complete required continuing-education on opioid prescribing and pain management; that patients disclose prior controlled-substance prescriptions to subsequent prescribers; and that prescribers consult the Texas Prescription Monitoring Program (PMP) before prescribing certain controlled substances. Violations of these regulatory provisions are independently sanctionable by the Texas Medical Board, the Texas State Board of Pharmacy, and other licensing authorities — and they supply the regulatory backdrop for § 481.129 criminal prosecutions.

The Texas PMP, operated by the Texas State Board of Pharmacy under the "Aware" database, receives near-real-time dispensing data from every Texas pharmacy and supplies the investigative backbone for doctor-shopping prosecutions. Texas investigators routinely run PMP queries on suspected doctor-shoppers and prescriber suspects, producing comprehensive dispensing histories that can support § 481.129 charges. The PMP data is also discoverable evidence at trial and frequently figures in defense investigation — examination of the data can reveal whether the defendant's prescribing or filling patterns were genuinely outliers relative to peer practitioners, whether prescriptions were properly checked against the PMP under the practitioner rules, and whether legitimate medical-need patterns explain apparently anomalous dispensing data.

Texas-court charging decisions on § 481.129 frequently incorporate co-charges under related statutes. Common companion charges include § 32.21 forgery (forging a prescription as a "writing"); § 32.51 fraudulent use or possession of identifying information (using stolen identities to obtain prescriptions); § 35A.02 Medicaid fraud (where state-funded prescriptions are involved); and § 28.03 criminal mischief or related theft offenses where prescription pads or DEA-registration numbers were stolen. The companion-charge stacking can substantially increase exposure beyond the underlying § 481.129 grade, and the defense must address each prong in plea negotiation and trial strategy.

Defense strategies for prescription drug fraud

Defense strategies in prescription fraud cases cluster around Ruan good-faith knowledge defense for prescribers, legitimate medical purpose challenges under § 1306.04, DEA red-flags methodology challenges, standard-of-care expert testimony, § 481.129 mens-rea challenges, and TMB administrative-proceeding coordination.

Defending a federal or state prescription drug fraud case is a multi-front exercise that must integrate criminal, administrative-licensing, civil malpractice, and (in pill-mill cases) FCA or qui tam exposure into a single coherent strategy. The defense team for a prescriber prosecution typically includes white-collar criminal counsel, healthcare-regulatory counsel, and Texas Medical Board licensing-defense counsel — with the criminal defense lead coordinating the overall strategy. The defense for a patient or non-licensed defendant is typically more streamlined — focusing primarily on the criminal defense and any related substance-use-disorder treatment that may support sentencing-mitigation arguments.

For prescribers, the central defense theory in most post-Ruan cases is the subjective good-faith medical judgment defense. The defendant produces evidence — through testimony, contemporaneous documentation, and standard-of-care expert testimony — that he believed his prescribing was within the usual course of professional practice and issued for legitimate medical purpose. The evidence typically includes treatment plans, clinical notes documenting medical decision-making, urine drug screens and pain-contract compliance documentation, consultation records, continuing-education completion, and where appropriate testimony from the defendant's own treating-physician peer group. Standard-of-care expert testimony — typically from a board-certified pain-medicine, addiction-medicine, or specialty-specific expert — addresses both the objective question of whether the prescribing fell within professional norms and the subjective question of whether a reasonable practitioner in the defendant's position would have understood the prescribing as legitimate.

The DEA red-flags methodology used by the government to identify pill-mill prosecutions can itself be challenged. Defense counsel routinely cross-examines DEA Diversion Investigators and government experts on the methodological soundness of the red-flags framework, the selection of comparison practitioners, the failure to account for patient-population characteristics (e.g., specialty practice serving genuinely high-need patients), and the conflation of legitimate-but-aggressive pain management with diversion. Patient-record analysis routinely surfaces medical justifications for prescribing patterns that the government characterized as red flags. Where the defense can demonstrate that the defendant's patient population was genuinely high-need or that the prescribing patterns followed established pain-medicine clinical practice guidelines, the red-flags evidence is substantially weakened.

For patients and non-prescriber defendants under § 843(a)(3) or § 481.129, the principal defense theories focus on (1) negating the mens rea — the defendant did not knowingly engage in fraud or deception (relied on the prescriber, was unaware of duplicative prescriptions, did not understand reporting requirements); (2) challenging documentary evidence through forensic-document examination (forgery and alteration claims can be defeated by handwriting and ink analysis); (3) Fourth Amendment challenges to pharmacy and clinic record obtainment; (4) statute-of-limitations defenses on older counts; and (5) substance-use-disorder mitigation, frequently coordinated with diversion-court eligibility analysis under specialty docket programs available in many Texas counties and federal districts.

DEA red-flags methodology and how to challenge it

The DEA Diversion Control Division's "red flags" framework identifies prescribing patterns inconsistent with legitimate practice — high opioid volumes, geographic dispersion, cash-only payments, "Houston cocktail" combinations, and short patient encounters. Defense counsel routinely challenges methodology, comparison-group selection, and the conflation of aggressive pain management with diversion.

The DEA Diversion Control Division's investigative methodology for identifying pill-mill prescribers is articulated in agency practitioner-manual guidance and in expert testimony presented at federal trials. The framework identifies certain prescribing or dispensing patterns as "red flags" — circumstantial indicators that the controlled-substance distribution may be unauthorized within the meaning of 21 U.S.C. § 841 and 21 C.F.R. § 1306.04. The principal red flags include (1) unusually high opioid-prescription volumes; (2) disproportionate Schedule II prescribing relative to peer practitioners; (3) geographically dispersed patient bases — patients traveling unusually long distances for prescriptions, particularly across state lines; (4) cash-only or fee-for-visit payment patterns inconsistent with insurance-billed practice; (5) prescribing of "dangerous combinations" — opioid plus benzodiazepine plus muscle relaxant (the "Houston cocktail" or "trinity"); (6) prescribing of identical doses and combinations to multiple patients regardless of individual presentation; (7) early refills and pattern of "no-show" appointments followed by full prescriptions; (8) very short patient encounters (under 5-10 minutes); and (9) limited or no physical examinations.

The red-flags framework operates as both an investigative-targeting tool and a trial-evidence category. DEA Diversion Investigators use the framework to identify practitioners for investigation, typically combining red-flags analysis with PMP-data analytics, patient interviews, undercover beneficiary encounters, financial-records analysis, and clinic-staff interviews. At trial, DEA agents and government-retained experts testify to the red-flags methodology and connect specific prescribing patterns at the defendant's practice to the red-flags categories. The testimony is used to support the jury inference that the defendant subjectively knew the prescribing was outside the usual course of professional practice — particularly after Ruan, where the subjective-knowledge element is now controlling.

Defense counsel routinely challenges red-flags testimony on multiple grounds. Methodological soundness: the DEA red-flags framework has not been subjected to peer-reviewed validation as a diagnostic tool for diversion, and the criteria are not consistently applied across investigators. Comparison-group selection: the choice of peer practitioners against which the defendant's prescribing volumes are compared often fails to account for the defendant's specialty (pain medicine, addiction medicine, palliative care) or patient-population characteristics (high-need pain patients, post-surgical patients, hospice). Conflation with legitimate aggressive prescribing: clinical pain-medicine practice guidelines from organizations like the American Society of Interventional Pain Physicians and the American Academy of Pain Medicine routinely call for higher-dose, longer-duration prescribing in certain patient populations than would be considered "normal" for a general-practice physician — testimony that flags such prescribing as suspicious can be challenged on standard-of-care grounds.

Standard-of-care expert testimony is the principal counter to red-flags testimony. The defense retains a board-certified pain-medicine, addiction-medicine, or specialty-appropriate expert — typically a physician with both clinical practice experience and academic credentials — to provide opinion testimony on whether the defendant's prescribing patterns were within the standard of care for the relevant specialty. The expert reviews the patient records, the prescribing patterns, the documentation, and the defendant's clinical reasoning, and provides opinion testimony supporting the legitimate medical purpose of the prescribing. The expert typically also addresses the specific red flags identified by the government and provides explanations consistent with legitimate practice. Effective standard-of-care expert testimony can substantially undermine the government's case and is often dispositive of the jury's verdict.

Local DFW practice — NDTX and EDTX pill-mill prosecutions and the TMB parallel

The Northern and Eastern Districts of Texas have been active venues for pill-mill prosecutions. The Texas Medical Board administrative track runs in parallel — license suspensions, restrictions, and revocations can produce immediate professional consequences regardless of the criminal disposition.

The Northern District of Texas (sitting in Dallas, Fort Worth, Amarillo, Lubbock, San Angelo, Abilene, and Wichita Falls divisions) and the Eastern District of Texas (sitting in Sherman, Plano, Tyler, Texarkana, Beaumont, Marshall, and Lufkin divisions) have been active forums for pill-mill prosecutions over the past decade. The DOJ Healthcare Fraud Strike Force unit based in Dallas, which has operated continuously since 2018, has handled the largest of these cases — including multi-defendant indictments involving organized clinic operations, pharmacy diversion networks, and patient-recruitment schemes. Smaller prescriber prosecutions and substantially all patient prosecutions under § 843(a)(3) are handled by the AUSA narcotics and healthcare-fraud sections rather than the Strike Force.

Texas state-court prosecutions under § 481.129 originate primarily with DPS Narcotics Division investigations, county-level narcotics task forces, and pharmacy-board referrals. Collin, Dallas, Denton, and Tarrant Counties — the four-county DFW core — produce a substantial volume of § 481.129 cases each year, with most resolving through plea agreements involving probation or short state-jail-felony custody for lower-level offenders. PG1/PG2 § 481.129 cases involving organized doctor-shopping or repeat-offender patterns produce 3rd-degree felony exposure (2-10 years) that frequently results in TDCJ sentences in the 2-5 year range upon conviction.

The Texas Medical Board administrative track operates in parallel to either the federal or state criminal proceedings and produces consequences independently of the criminal disposition. Under Texas Occupations Code §§ 164.051-164.058, the TMB can suspend, restrict, revoke, or refuse to renew a physician's license based on (1) violation of the Texas Controlled Substances Act or comparable federal law, (2) failure to practice medicine in an acceptable professional manner consistent with public health and welfare, (3) conviction of a felony or crime of moral turpitude, or (4) a number of other specified grounds. The TMB process typically begins with a complaint (frequently filed by DEA, DPS, or a pharmacy whistleblower), proceeds through an Investigation Division review, and culminates in an Informal Settlement Conference or — if not resolved — a State Office of Administrative Hearings (SOAH) contested-case hearing.

Coordinating defense strategy across the criminal case and the TMB proceeding is critical. The TMB may proceed to license action substantially faster than the criminal case proceeds to disposition — and the defendant's ability to continue practicing medicine (and earning income) may be foreclosed before the criminal case is resolved. At the same time, statements made in the TMB proceeding can be used in the criminal case, and the TMB process involves disclosures that may have Fifth Amendment implications. The defense team must structure the TMB defense to preserve criminal defenses where possible while still advancing arguments that may save or restrict the medical license. Similar parallel-proceeding issues arise with the Texas State Board of Pharmacy (for pharmacist defendants), the DEA Administrative Law Judge process (for DEA registration revocation), HHS-OIG exclusion proceedings (for federal-program billing exclusion), CMS Medicare billing privilege revocation, and state Medicaid exclusion.

When to retain counsel — search warrants, target letters, and TMB complaints

The right time to retain prescription fraud defense counsel is the day of a search warrant execution, a target letter, a DEA Diversion Investigator interview request, a TMB complaint notice, or a § 481.129 arrest. Early counsel preserves privilege, manages records, and coordinates across criminal and licensing tracks.

The earliest moment to retain federal or Texas prescription fraud defense counsel is the first sign of government interest. For prescribers, that typically takes the form of (1) a DEA Diversion Investigator request for an interview or records; (2) a federal grand jury subpoena to the practice or to a billing or pharmacy vendor; (3) a target letter from a U.S. Attorney's Office; (4) a search warrant executed at the office, clinic, or home; (5) a Texas Medical Board complaint notice or Investigation Division contact; (6) a Texas DPS Narcotics Division contact; or (7) a parallel pharmacy board, OIG, or CMS administrative inquiry. For patients, the typical first indicators are (1) a pharmacy refusal to fill a prescription based on PMP findings; (2) a DPS or DEA agent interview request; (3) a § 481.129 arrest; (4) a federal arrest on § 843(a)(3) charges; or (5) a grand jury subpoena to testify in a pill-mill investigation targeting a prescriber.

For prescribers, the immediate steps after first government contact are (1) decline any unannounced interview without counsel present (DEA Diversion Investigators and DPS agents are skilled investigators who routinely produce inculpatory statements during "informal" interviews); (2) implement a litigation hold on patient records, billing records, financial records, communications, and security-camera footage; (3) preserve attorney-client privilege through prompt counsel engagement; (4) identify whether parallel TMB or administrative proceedings are pending; (5) coordinate with healthcare-regulatory counsel on PMP query history and DEA compliance documentation; and (6) assess parallel qui tam or FCA civil exposure where any federal-program billing is involved. The defense team typically includes white-collar criminal counsel, healthcare-regulatory counsel, and TMB licensing-defense counsel.

Records management for prescriber defendants involves substantial complexity. Patient medical records are covered by HIPAA and must be produced in compliance with applicable privacy rules. DEA recordkeeping requirements under 21 C.F.R. § 1304 produce a parallel set of records (DEA Form 222 records, dispensing logs, inventory records) that must be preserved and produced. Billing records, financial records (including bank statements, payment-processing records, and asset-acquisition records), employee personnel files, and electronic records (EHR system, scheduling system, communications) all require independent preservation and review. A poorly executed records production can result in inadvertent privilege waiver, missing-evidence sanctions, or production of materials that materially harm the defense. Vendor selection for e-discovery and structured records review begins in the first 30 days of representation.

For patients and non-prescriber defendants under § 843(a)(3) or § 481.129, the immediate priorities are different. Counsel's job is to (1) assess the strength of the documentary evidence — prescription forgeries, PMP queries, pharmacy records, surveillance materials; (2) assess Fourth Amendment defenses to any evidence obtained through pharmacy or clinic records without proper legal process; (3) identify substance-use-disorder treatment that may support diversion-court eligibility or sentencing mitigation; (4) develop the mens-rea defense — what the defendant knew about the prescriber's practices, about prior prescriptions, about the reporting requirements; and (5) coordinate with any pending Texas Medical Board proceeding if the defendant holds a healthcare license. The defense for a patient or non-licensed defendant is typically less complex than for a prescriber but still requires careful early-case work to preserve the best available defenses.